InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（3 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
3
T+90 胜率
0%
T+90 平均收益
-30.8%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the detailed record of transactions filed by Posard Matthew L., Director. Officer active across 3 companies, notably Halozyme Therapeutics, INC.. Aggregated, 12 reports have been logged. Split: 1 buy · 3 sells. Total volume traded: €1.6m. Activity tracked since 5 May 2021. The latest transaction was filed on 1 May 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Posard Matthew L.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报12 总计
4,165 股0Common StockSEC:0001415889-25-011777:0
10,000 股@ US$55.72333.2% 占其流量Common StockSEC:0001415889-24-021305:0
10,000 股@ US$50.01130.4% 占其流量Common StockSEC:0001415889-24-016672:0
6,501 股0Common StockSEC:0001415889-24-011705:0
35,714 股0Common StockSEC:0001209191-23-034582:0
8,065 股0Common StockSEC:0001415889-23-007694:0
10,000 股@ US$58.8036.4% 占其流量Common StockSEC:0001415889-22-012142:0
26,480 股0Common StockSEC:0001209191-22-032989:0
6,206 股0Restricted Stock UnitsSEC:0001179110-22-002912:0
20,000 股@ US$4.570.033% mcap50.0% 占其流量Common StockSEC:0001808805-21-000026:0
标准退出：2022年2月28日 (T+90)
4,497 股0Common StockSEC:0001209191-21-036712:0
5,230 股0Restricted Stock UnitsSEC:0001179110-21-004974:0
12 条申报中的 12 条
About Posard Matthew L.
Posard Matthew L. is a Director at HALOZYME THERAPEUTICS, INC., DermTech, Inc., and Nautilus Biotechnology, Inc. He plays a key role in the governance of these companies, contributing to strategic decision-making and overseeing operations. His experience in the biopharmaceutical sector is a valuable asset.
